Lead Product(s) : Samelisant
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Suven Life Sciences to Present phase-2 Results on Samelisant at AAN 2024
Details : SUVN-G3031 (samelisant), potent and selective histamine H3 receptor inverse agonist, is being developed for excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy.
Brand Name : SUVN-G3031
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2024
Lead Product(s) : Samelisant
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?